Document is current
Any future updates will be listed below
-
Authors
Alicic, Radica Z. https://orcid.org/0000-0002-5437-5700
Neumiller, Joshua J. https://orcid.org/0000-0002-4734-7402
Tuttle, Katherine R. https://orcid.org/0000-0002-2235-0103
- License Information
-
More Information
Article History
Accepted: 13 November 2025
First Online: 8 January 2026
Competing interests
: R.Z.A. is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc, the Doris Duke Charitable Foundation, Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly. J.J.N. is supported by NIH research grant OT2OD032581 and a research grant from the American College of Clinical Pharmacy, reports consulting fees from Bayer AG, Sanofi, Boehringer Ingelheim, Eli Lilly and Proteomics International, reports payments for lectures from Dexcom and Med Learning Group and serves on the Board of Directors for the American Diabetes Association. K.R.T. is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264. She has also received investigator-initiated grant support from Travere Therapeutics Inc, Bayer, the Doris Duke Charitable Foundation and Breakthrough T1D. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Novo Nordisk, Travere Therapeutics Inc, ProKidney and Alnylam; and speaker fees from Novo Nordisk Boehringer Ingelheim and Bayer.
